IC 265 is being developed for the treatment of dry eye
Dry eye disease (DED) is a chronic inflammatory condition affecting 26 million patients in Japan and South Korea.
IC 265 is being developed with the ability to significantly improve both the safety and efficacy of existing DED therapies.

In a Phase 2 conjunctival allergy challenge study, IC 265 demonstrated the following:

IC 265: Development strategy
Scientific and clinical validation
Completed Phase 2 in Conjunctival Allergen Challenge (CAC) model as proof of concept (POC) for ocular surface inflammation
Positive POC for ocular surface activity in reducing redness and demonstrated anti-inflammatory effect
IC 265 concentrations were found well tolerated in the Phase 2 study
Formulation
Manufacturing clinical supplies for Good Manufacturing Practice (GMP)
Clinical Development
Open Investigational New Drug (IND) application with US FDA
Planned Phase 2 parallel-group study in dry eye patients
View other products